pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
Buprenorphine + naloxone (Suboxone)
Approved · small molecule · Opiate Dependence
Buprenorphine + naloxone (Suboxone) for Opiate Dependence is a Approved program (small_molecule) at Indivior Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code BU0808
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Indivior Pty Ltd
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Opiate Dependence
- Status
- completed
- Trials
- 1